These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 2405360)

  • 21. Cyclosporine combined with methylprednisolone or methotrexate in prophylaxis of moderate to severe acute graft-versus-host disease.
    Gondo H; Harada M; Taniguchi S; Akashi K; Hayashi S; Teshima T; Takamatsu Y; Eto T; Nagafuji K; Yamasaki K
    Bone Marrow Transplant; 1993 Nov; 12(5):437-41. PubMed ID: 8298553
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hematopoietic growth factors after HLA-identical allogeneic bone marrow transplantation in patients treated with methotrexate-containing graft-vs.-host disease prophylaxis.
    Martin-Algarra S; Bishop MR; Tarantolo S; Cowles MK; Reed E; Anderson JR; Vose JM; Bierman P; Armitage JO; Kessinger A
    Exp Hematol; 1995 Dec; 23(14):1503-8. PubMed ID: 8542938
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A multicenter, randomized, double-blind comparison of different doses of intravenous immunoglobulin for prevention of graft-versus-host disease and infection after allogeneic bone marrow transplantation.
    Winston DJ; Antin JH; Wolff SN; Bierer BE; Small T; Miller KB; Linker C; Kaizer H; Lazarus HM; Petersen FB; Cowan MJ; Ho WG; Wingard JR; Schiller GJ; Territo MC; Jiao J; Petrarca MA; Tonetta SA
    Bone Marrow Transplant; 2001 Jul; 28(2):187-96. PubMed ID: 11509937
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination prophylactic immunosuppression in bone marrow transplantation.
    Szer J
    Transplant Proc; 1989 Feb; 21(1 Pt 3):3011-2. PubMed ID: 2650415
    [No Abstract]   [Full Text] [Related]  

  • 25. Microangiopathy following allogeneic marrow transplantation. Association with cyclosporine and methylprednisolone for graft-versus-host disease prophylaxis.
    Kalhs P; Brugger S; Schwarzinger I; Greinix HT; Keil F; Kyrle PA; Knöbl P; Schneider B; Höcker P; Linkesch W
    Transplantation; 1995 Nov; 60(9):949-57. PubMed ID: 7491699
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cyclosporin A and mini short-term methotrexate vs cyclosporin A as graft-versus-host disease prophylaxis in patients with beta thalassemia major undergoing allogeneic blood and marrow transplantation.
    Iravani M; Mousavi A; Gholibeikian S; Bahar B; Samiee S; Ashouri A; Eghbal L; Ghavamzadeh A
    Bone Marrow Transplant; 2005 Jun; 35(11):1095-9. PubMed ID: 15821773
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Marrow transplantation for leukemia and aplastic anemia: two controlled trials of a combination of methotrexate and cyclosporine v cyclosporine alone or methotrexate alone for prophylaxis of acute graft-v-host disease.
    Storb R; Deeg HJ; Whitehead J; Farewell V; Appelbaum FR; Beatty P; Bensinger W; Buckner CD; Clift RA; Doney K
    Transplant Proc; 1987 Feb; 19(1 Pt 3):2608-13. PubMed ID: 3547942
    [No Abstract]   [Full Text] [Related]  

  • 28. [Prophylaxis of acute graft-versus-host disease after allogeneic bone marrow transplantation--combination protocol of high dose methylprednisolone, prednisolone and methotrexate].
    Shinohara Y; Kai S; Misawa M; Fujimori Y; Okamoto T; Kohsaki M; Kanamaru A; Ifuku H; Ohe Y; Hara H
    Rinsho Ketsueki; 1986 Jan; 27(1):30-5. PubMed ID: 3520045
    [No Abstract]   [Full Text] [Related]  

  • 29. Combination low-dose thalidomide and cyclosporine prophylaxis for acute graft-versus-host disease in a rat mismatched model.
    Vogelsang GB; Wells MC; Santos GW; Chen TL; Hess AD
    Transplant Proc; 1988 Apr; 20(2 Suppl 2):226-8. PubMed ID: 3284069
    [No Abstract]   [Full Text] [Related]  

  • 30. Impact of cyclosporine and methylprednisolone dose used for prophylaxis and therapy of graft-versus-host disease on survival and relapse after allogeneic bone marrow transplantation.
    Michallet M; Perrin MC; Belhabri A; Molina L; Nicolini F; Tigaud JD; Sotto JJ; Guyotat D; Fière D; Archimbaud E
    Bone Marrow Transplant; 1999 Jan; 23(2):145-50. PubMed ID: 10197799
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Results of four different protocols for prophylaxis against graft-versus-host disease.
    Tollemar J; Ringdén O; Bäckman L; Janossy G; Lönnqvist B; Markling L; Philstedt P; Sundberg B
    Transplant Proc; 1989 Feb; 21(1 Pt 3):3008-10. PubMed ID: 2650414
    [No Abstract]   [Full Text] [Related]  

  • 32. Continuous infusion cyclosporine and nifedipine to day +100 with short methotrexate and steroids as GVHD prophylaxis in unrelated donor transplants.
    Liesveld J; Duerst R; Rapoport A; Constine L; Abboud C; Packman C; Wedow L; Zwetsch L; McKenna B; Linder T; Silverman W; Swift S; Rowe J; DiPersio J
    Bone Marrow Transplant; 1999 Sep; 24(5):511-6. PubMed ID: 10482935
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Omission of day 11 methotrexate does not appear to influence the incidence of moderate to severe acute graft-versus-host disease, chronic graft-versus-host disease, relapse rate or survival after HLA-identical sibling bone marrow transplantation.
    Atkinson K; Downs K
    Bone Marrow Transplant; 1995 Dec; 16(6):755-8. PubMed ID: 8750265
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevention of graft-versus-host disease on an individual basis.
    Aschan J; Ringdén O; Andström E; Ljungman P; Remberger M
    Transplant Proc; 1994 Jun; 26(3):1823-4. PubMed ID: 8030155
    [No Abstract]   [Full Text] [Related]  

  • 35. Prognostic factors for long-term survival in leukemic marrow recipients with special emphasis on age and prophylaxis for graft-versus-host disease.
    Aschan J; Ringdén O
    Clin Transplant; 1994 Jun; 8(3 Pt 1):258-70. PubMed ID: 8061365
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Prophylaxis with FK-506 for graft-versus-host disease after transplantation of bone marrow from unrelated donors].
    Hamazaki T; Yagi K; Inoue M; Sakata N; Okamura T; Yasui M; Sasabe M; Kishimoto T; Inoue A; Kawa K
    Rinsho Ketsueki; 2000 May; 41(5):430-6. PubMed ID: 10879106
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Six weeks of continuous intravenous cyclosporine and short-course methotrexate as prophylaxis for acute graft-versus-host disease after allogeneic bone marrow transplantation.
    Beelen DW; Quabeck K; Kaiser B; Wiefelspütz J; Scheulen ME; Graeven U; Grosse-Wilde H; Sayer HG; Schaefer UW
    Transplantation; 1990 Sep; 50(3):421-7. PubMed ID: 2402791
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of immunosuppressive drugs for prevention of graft-v-host disease after bone marrow transplantation.
    Devergie A; Esperou H; Traineau R; Varrin F; Lehn P; Gluckman E
    Nouv Rev Fr Hematol (1978); 1989; 31(2):73-5. PubMed ID: 2671932
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Peripheral blood versus bone marrow as a source of hematopoietic stem cells for allogeneic transplantation in children with class I and II beta thalassemia major.
    Ghavamzadeh A; Iravani M; Ashouri A; Mousavi SA; Mahdavi N; Shamshiri A; Hadjibabaie M; Namdar R; Nedaeifard L; Ghaffari H; Alimoghaddam K
    Biol Blood Marrow Transplant; 2008 Mar; 14(3):301-8. PubMed ID: 18275896
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation.
    Bacigalupo A; Lamparelli T; Barisione G; Bruzzi P; Guidi S; Alessandrino PE; di Bartolomeo P; Oneto R; Bruno B; Sacchi N; van Lint MT; Bosi A;
    Biol Blood Marrow Transplant; 2006 May; 12(5):560-5. PubMed ID: 16635791
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.